Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

CXCR4 nanobodies (VHH-based single variable domains) potently inhibit chemotaxis and HIV-1 replication and mobilize stem cells.

Jähnichen S, Blanchetot C, Maussang D, Gonzalez-Pajuelo M, Chow KY, Bosch L, De Vrieze S, Serruys B, Ulrichts H, Vandevelde W, Saunders M, De Haard HJ, Schols D, Leurs R, Vanlandschoot P, Verrips T, Smit MJ.

Proc Natl Acad Sci U S A. 2010 Nov 23;107(47):20565-70. doi: 10.1073/pnas.1012865107. Epub 2010 Nov 8.

2.

Production, characterization and in vitro testing of HBcAg-specific VHH intrabodies.

Serruys B, Van Houtte F, Farhoudi-Moghadam A, Leroux-Roels G, Vanlandschoot P.

J Gen Virol. 2010 Mar;91(Pt 3):643-52. doi: 10.1099/vir.0.016063-0. Epub 2009 Nov 4.

PMID:
19889923
3.

Llama-derived single-domain intrabodies inhibit secretion of hepatitis B virions in mice.

Serruys B, Van Houtte F, Verbrugghe P, Leroux-Roels G, Vanlandschoot P.

Hepatology. 2009 Jan;49(1):39-49. doi: 10.1002/hep.22609.

PMID:
19085971
4.

Contamination of a recombinant hepatitis B virus nucleocapsid preparation with a human B-cell activator.

Vanlandschoot P, Van Houtte F, Serruys B, Leroux-Roels G.

J Virol. 2007 Mar;81(5):2535-6. Epub 2006 Dec 6. No abstract available.

5.

Supplemental Content

Loading ...
Support Center